Bio-Rad

The firm saw modest growth across both of its business segments and double-digit growth in its droplet digital PCR product line.

he lawsuit, filed on the eve of 10x's IPO, alleges that 10x's new Next GEM microfluidic chips infringe a patent exclusively licensed to Bio-Rad.

The index, which slightly underperformed the Dow Jones, had a smaller loss in August than in the previous month.

Neogen this week announced that its NeoSeek genetic test for Shiga toxin-producing strains of Escherichia coli (STEC) has received validation from AOAC.

In addition to the $24 million jury verdict, 10x must pay an additional $8.3 million in damages and $2.2 million in interest. It has appealed the case.

The life science segment saw strong sales in Droplet Digital PCR offset by sales the firm's process media product line.

The exact restrictions the injunction will place on 10x are not yet determined. 10x will also have to pay Bio-Rad additional damages, plus interest.

A federal judge upheld a $24 million jury award to Bio-Rad, while a trade court judge said Bio-Rad imported microfluidics that infringed 10x patents.